Altimmune to start late-stage trial for MASH candidate this year

Altimmune (ALT) stock dips as higher-than-expected R&D costs lead to a Q4 2025 earnings miss for the company. Read more here.

My LFT is slightly high, but I feel fine”: Doctors explain when borderline liver reports turn dangerous and what should be the immediate preventive measures

LFT slightly high. There is no pain. No yellowing of the eyes. No weakness. So it is easy to brush it aside. But the liver rarely shouts in the beginning. It whispers.Liver Function Tests, or LFTs, ...

Nuvation Bio Inc.: Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Successfully started 216 patients on IBTROZI® (taletrectinib) in the fourth quarter of 2025, for a total of 432 new patient starts since launch in the second half of ...